Select Vaccines signs agreement to develop Hep C test
Thursday, 25 March, 2004
Select Vaccines (ASX: SLT) has signed a materials transfer agreement (MTA) with a multinational biotechnology company to access materials it will use to accelerate the development of its hepatitis C rapid diagnostic test.
"It's one in a series of MTAs which will put us in the best possible position to have a rapid test that works with a number of rapid systems in the marketplace," said CEO Dr Martin Soust.
Soust said the agreement would cut at least three months off the timeframe required to develop the point-of-care test, and would allow the company to compare multiple rapid systems concurrently.
The MTA also contains the provision that the supplier company will be able to exercise rights to license or on-license any IP that arises from successful development.
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
Australia's first cases of H5 avian influenza confirmed
Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
